Logo image of SEQUA.BR

SEQUANA MEDICAL NV (SEQUA.BR) Stock Fundamental Analysis

EBR:SEQUA - Euronext Brussels - BE0974340722 - Common Stock - Currency: EUR

1.238  -0.03 (-2.21%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to SEQUA. SEQUA was compared to 57 industry peers in the Health Care Equipment & Supplies industry. SEQUA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, SEQUA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SEQUA has reported negative net income.
In the past year SEQUA has reported a negative cash flow from operations.
SEQUA had negative earnings in each of the past 5 years.
In the past 5 years SEQUA always reported negative operating cash flow.
SEQUA.BR Yearly Net Income VS EBIT VS OCF VS FCFSEQUA.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

SEQUA has a Return On Assets of -449.06%. This is amonst the worse of the industry: SEQUA underperforms 94.74% of its industry peers.
Industry RankSector Rank
ROA -449.06%
ROE N/A
ROIC N/A
ROA(3y)-296.55%
ROA(5y)-236.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SEQUA.BR Yearly ROA, ROE, ROICSEQUA.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SEQUA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SEQUA.BR Yearly Profit, Operating, Gross MarginsSEQUA.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

0

2. Health

2.1 Basic Checks

SEQUA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SEQUA has more shares outstanding
Compared to 5 years ago, SEQUA has more shares outstanding
The debt/assets ratio for SEQUA is higher compared to a year ago.
SEQUA.BR Yearly Shares OutstandingSEQUA.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SEQUA.BR Yearly Total Debt VS Total AssetsSEQUA.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

SEQUA has an Altman-Z score of -46.28. This is a bad value and indicates that SEQUA is not financially healthy and even has some risk of bankruptcy.
SEQUA has a worse Altman-Z score (-46.28) than 91.23% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -46.28
ROIC/WACCN/A
WACC5.77%
SEQUA.BR Yearly LT Debt VS Equity VS FCFSEQUA.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M -40M

2.3 Liquidity

SEQUA has a Current Ratio of 0.12. This is a bad value and indicates that SEQUA is not financially healthy enough and could expect problems in meeting its short term obligations.
SEQUA has a worse Current ratio (0.12) than 94.74% of its industry peers.
SEQUA has a Quick Ratio of 0.12. This is a bad value and indicates that SEQUA is not financially healthy enough and could expect problems in meeting its short term obligations.
SEQUA's Quick ratio of 0.08 is on the low side compared to the rest of the industry. SEQUA is outperformed by 94.74% of its industry peers.
Industry RankSector Rank
Current Ratio 0.12
Quick Ratio 0.08
SEQUA.BR Yearly Current Assets VS Current LiabilitesSEQUA.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.40% over the past year.
SEQUA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -85.19%.
The Revenue for SEQUA have been decreasing by -35.84% on average. This is quite bad
EPS 1Y (TTM)1.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40.68%
Revenue 1Y (TTM)-85.19%
Revenue growth 3Y-34.21%
Revenue growth 5Y-35.84%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, SEQUA will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.29% on average per year.
SEQUA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 666.97% yearly.
EPS Next Y47.62%
EPS Next 2Y14.29%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year733.33%
Revenue Next 2Y666.97%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SEQUA.BR Yearly Revenue VS EstimatesSEQUA.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
SEQUA.BR Yearly EPS VS EstimatesSEQUA.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SEQUA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SEQUA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SEQUA.BR Price Earnings VS Forward Price EarningsSEQUA.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SEQUA.BR Per share dataSEQUA.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as SEQUA's earnings are expected to grow with 14.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.29%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SEQUA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SEQUANA MEDICAL NV

EBR:SEQUA (7/18/2025, 7:00:00 PM)

1.238

-0.03 (-2.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-03 2025-04-03/amc
Earnings (Next)N/A N/A
Inst Owners49.23%
Inst Owner ChangeN/A
Ins Owners5.87%
Ins Owner ChangeN/A
Market Cap70.86M
Analysts83.64
Price Target4.05 (227.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)15.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-92.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 671.69
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS-0.78
TBVpS-0.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -449.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-296.55%
ROA(5y)-236.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.46%
Cap/Sales 90.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.12
Quick Ratio 0.08
Altman-Z -46.28
F-Score2
WACC5.77%
ROIC/WACCN/A
Cap/Depr(3y)113.39%
Cap/Depr(5y)92.99%
Cap/Sales(3y)87.76%
Cap/Sales(5y)73.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40.68%
EPS Next Y47.62%
EPS Next 2Y14.29%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-85.19%
Revenue growth 3Y-34.21%
Revenue growth 5Y-35.84%
Sales Q2Q%-100%
Revenue Next Year733.33%
Revenue Next 2Y666.97%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.97%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.3%
OCF growth 3YN/A
OCF growth 5YN/A